← Back to Search

Vitamin

Nicotinamide for Alzheimer's Disease (NEAT Trial)

Phase 2
Waitlist Available
Led By Joshua Grill, Ph.D.
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 48 weeks
Awards & highlights

NEAT Trial Summary

This trial is testing whether nicotinamide (vitamin B3) can reduce the amount of tau protein in people with mild Alzheimer's disease.

Eligible Conditions
  • Alzheimer's Disease
  • Mild Cognitive Impairment

NEAT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 48 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 48 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in P-tau 231
Change in QTC
Columbia-Suicide Severity Rating Scale
+9 more
Secondary outcome measures
ADASCog-13
Activities of Daily Living - Mild Cognitive Impairment
CDR Sum of Boxes
+6 more

Side effects data

From 2022 Phase 2 trial • 46 Patients • NCT03061474
25%
Diarrhoea
17%
Fall
17%
Urinary tract infection
8%
Vomiting
8%
Anxiety
8%
Back pain
8%
Laboratory test abnormal
8%
Constipation
4%
Transaminases increased
4%
Post lumbar puncture syndrome
4%
Head Injury
4%
Dyspepsia
4%
Upper respiratory tract infection
4%
Arthralgia
4%
Headache
4%
Neuropathy peripheral
4%
Rash
4%
Fungal infection
4%
Penile ulceration
4%
Syncoper
4%
Foot fracture
4%
Osteoporosis
4%
Tooth abscess
4%
Agitation
4%
Weight decreased
4%
Blood testosterone decreased
4%
Hiatus hernia
4%
Urticaria
4%
Pleocytosis
4%
Actinic keratosis
4%
Viral upper respiratory tract infection
4%
Thrombocytopenia
4%
Hyperlipidaemia
4%
Laceration
4%
Limb injury
4%
Miliaria
4%
Pneumonia
4%
Diabetes mellitus
4%
Myalgia
4%
Colitis ulcerative
4%
Infection
4%
Coccydynia
4%
Cognitive disorder
4%
Renal cyst
4%
Colorectal cancer
4%
Parkinson's disease
4%
Dehydration
4%
Tremor
4%
Cancer surgery
4%
Glomerular Ffiltration rate decreased
4%
Vitamin D deficiency
4%
Foot deformity
4%
Hypokalaemia
4%
Psoriasis
4%
Dizziness
4%
Dysgeusia
4%
Basal cell carcinoma
4%
Eructation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Nicotinamide

NEAT Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NicotinamideExperimental Treatment1 Intervention
1500mg twice daily: 2, 750mg tablets taken orally twice daily
Group II: PlaceboPlacebo Group1 Intervention
1500mg twice daily: 2, 750mg tablets taken orally twice daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotinamide
2021
Completed Phase 3
~2810

Find a Location

Who is running the clinical trial?

University of California, IrvineLead Sponsor
544 Previous Clinical Trials
1,922,997 Total Patients Enrolled
Joshua Grill, Ph.D.Principal Investigator - Associate Professor of Psychiatry and Human Behavior
University of California, Irvine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Nicotinamide as an Early Alzheimer's Disease Treatment
Joshua Grill 2017. "Nicotinamide as an Early Alzheimer's Disease Treatment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03061474.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top